Kern Research, Inc.

Summary

Kern Research, Inc. is a medical facility located in Bakersfield, California. This center is recognized for care of Asthma, Chronic Urticaria, Atopic Dermatitis, Chronic Renal Failure, Chronic Kidney Disease and other specialties. Kern Research, Inc. is involved with conducting 31 clinical trials across 45 conditions. There are 2 research doctors associated with this hospital, such as Eric Boren and Rajeev Krishan, MD.

Top PIs

Clinical Trials running at Kern Research, Inc.

Asthma

Chronic Urticaria

Chronic Obstructive Pulmonary Disease

Cold Urticaria

Skin Writing

Cold hives

Injection Site Itch

Itching

Nasal polyps

Emphysema

Dupilumab

for Asthma

This trial is testing dupilumab, a medication that reduces lung inflammation, in adults with moderate to severe asthma that isn't controlled by usual treatments. It aims to see if dupilumab can help improve breathing and slow down lung damage.

Recruiting

2 awards

Phase 4

8 criteria

Dupilumab + ICS/LABA

for Asthma

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma medication. The aim of the study is to see which regimen is more effective: taking dupilumab with an inhaled asthma medication or only taking a higher dose of the inhaled asthma medication. The type of asthma medication that will be used is a combination inhaled corticosteroid and long-acting beta-agonist (referred to as an ICS/LABA). Some patients may also receive an additional asthma medication called a long-acting muscarinic antagonist (referred to as a LAMA) if they are already receiving a LAMA. The study is also looking at: • What side effects may happen from taking dupilumab

Recruiting

2 awards

Phase 4

5 criteria

Verekitug

for Asthma

The primary purpose of this study is to evaluate the long-term safety and efficacy of verekitug (UPB-101) in participants who complete the VALIANT study (NCT06196879).

Recruiting

0 awards

Phase 2